Evidence map›Paper›PMID 38945782›Full record

ArticleEuropean urology oncology2024

Enzalutamide Monotherapy in the EMBARK Trial Should Be Practice-changing and Existing Data Suggest How to Mitigate Toxicity.

Lisa M Cordes, Fatima Karzai, Ravi A Madan

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lisa M CordesGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Fatima KarzaiGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address: madanr@mail.nih.gov.

Funding

Evaluation of novel treatments in biochemically recurrent prostateZIABC011896 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MADAN, RAVI · 2019 to 2025
$3.6M
Natural History of Biochemically Recurrent Prostate CancerZIABC012118 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MADAN, RAVI · 2022 to 2025
$1.4M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Data from the EMBARK trial demonstrate the potential of enzalutamide monotherapy as an effective treatment for biochemically recurrent prostate cancer (BCR) without the side effects of testosterone-lowering therapy. Unfortunately, concerns about gynecomastia and how to manage this treatment-related toxicity have diminished enthusiasm. Existing data may offer an alternative scheduling strategy for enzalutamide monotherapy in BCR.

Indexed as

BenzamidesNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantAntineoplastic AgentsGynecomastiaHumansMaleNeoplasm Recurrence, LocalAntineoplastic AgentsBenzamidesenzalutamideNitrilesPhenylthiohydantoin

Identifiers

PMID38945782
PMCPMC11427149

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.